This Article Full Text Full Text (PDF) All Versions of this Article: 37/1/223    most recent 01.STR.0000196977.76702.6dv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Honda, F. Articles by Saito, N. Search for Related Content PubMed PubMed Citation Articles by Honda, F. Articles by Saito, N. Related Collections Acute Cerebral Infarction Brain Circulation and Metabolism Computerized tomography and Magnetic Resonance Imaging Antiplatelets

(Stroke. 2006;37:223.)
© 2006 American Heart Association, Inc.

Original Contributions

Cilostazol Attenuates Gray and White Matter Damage in a Rodent Model of Focal Cerebral Ischemia

Fumiaki Honda, MD; Hideaki Imai, MD, PhD; Makoto Ishikawa, PhD; Chisato Kubota; Tatsuya Shimizu, MD, PhD; Mari Fukunaga Nobuhito Saito, MD, PhD

From the Department of Neurosurgery (F.H., H.I., C.K., T.S., N.S.), Gunma University Graduate School of Medicine, Maebashi, Japan; and Tokushima Research Institute (M.I., M.F.), Otsuka Pharmaceutical Co., Tokushima, Japan.

Correspondence to Nobuhito Saito, MD, Department of Neurosurgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan. E-mail nsaito{at}med.gunma-u.ac.jp

Background and Purpose— To evaluate whether delayed treatment with the antiplatelet agent cilostazol reduces the volume of infarction in the gray and white matter in a rodent model of permanent focal cerebral ischemia and to explore the mechanism of the neuroprotective effect in vivo.

Methods— Cilostazol (30 or 50 mg/kg) or vehicle was administered by gavage 30 minutes and 4 hours after the induction of cerebral ischemia by permanent occlusion of the left middle cerebral artery (MCA). Animals were euthanized 24 hours after MCA occlusion, and the volume of gray matter damage was evaluated by quantitative histopathology. Axonal damage was determined with amyloid precursor protein immunohistochemistry. Dynamic susceptibility contrast MRI was used to assess regional cerebral blood volume (CBV) and cerebral blood flow (CBF).

Results— Treatment with the higher dose of cilostazol (50 mg/kg) significantly reduced the volume of gray matter damage and axonal damage in the cerebral hemisphere by 45.0% (P<0.02) and 42.4% (P<0.002), respectively, compared with the control group. Relative CBV in the peri-infarct area after MCA occlusion was significantly increased in the cilostazol-treated group (50 mg/kg) compared with the control group (P<0.05). Relative CBF tended to be higher in the cilostazol-treated group compared with the control group.

Conclusions— Treatment with cilostazol significantly reduced the gray and white matter damage associated with permanent focal ischemia. Cilostazol improved CBV and CBF in the peri-infarct area. The major action of cilostazol is to increase perfusion in the ischemic penumbra.

Key Words: cerebral ischemia, focal • neuroprotection • white matter

This article has been cited by other articles:

				E. Shi, X. Jiang, T. Kazui, N. Washiyama, K. Yamashita, H. Terada, and A. H. M. Bashar Controlled low-pressure perfusion at the beginning of reperfusion attenuates neurologic injury after spinal cord ischemia J. Thorac. Cardiovasc. Surg., April 1, 2007; 133(4): 942 - 948. [Abstract] [Full Text] [PDF]